Benitec Biopharma Inc. Earnings Per Share (Basic)
Benitec Biopharma Inc. (BNTC) reported Earnings Per Share (Basic) of -$0.98 per share for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-09-14
- Benitec Biopharma Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.26.
- Benitec Biopharma Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.24.
- Benitec Biopharma Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.26.
- Benitec Biopharma Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.22.
- Benitec Biopharma Inc. earnings per share, basic for fiscal 2026 was -$0.98.
- Benitec Biopharma Inc. earnings per share, basic for fiscal 2025 was -$1.05.
- Benitec Biopharma Inc. earnings per share, basic for fiscal 2024 was -$1.22.
- Benitec Biopharma Inc. earnings per share, basic for fiscal 2023 was -$14.12.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-09-14 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-09-14 | -$0.76 derived: net income ÷ weighted average shares · filed 2026-09-14 | -$0.98 10-K · filed 2026-09-14 | ||||
| 2026-03-31 | -$0.24 10-Q · filed 2026-05-14 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$0.72 10-Q · filed 2026-05-14 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-09-14 | ||||
| 2025-12-31 | -$0.26 10-Q · filed 2026-02-12 | -$0.48 10-Q · filed 2026-02-12 | -$0.69 derived: net income ÷ weighted average shares · filed 2026-09-14 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-09-14 | ||||
| 2025-09-30 | -$0.22 10-Q · filed 2025-11-14 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-09-14 | -$0.80 derived: net income ÷ weighted average shares · filed 2026-09-14 | -$1.06 derived: net income ÷ weighted average shares · filed 2026-09-14 | ||||
| 2025-06-30 | -$0.21 10-K/A · filed 2026-03-20 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-09-14 | -$0.84 derived: net income ÷ weighted average shares · filed 2026-09-14 | -$1.05 10-K · filed 2026-09-14 | ||||
| 2025-03-31 | -$0.38 10-Q · filed 2026-05-14 | -$0.24 10-Q · filed 2025-05-14 | -$0.63 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$0.84 10-Q · filed 2026-05-14 | -$0.63 10-Q · filed 2025-05-14 | -$1.04 derived: net income ÷ weighted average shares · filed 2026-05-14 | ||
| 2024-12-31 | -$0.26 10-Q · filed 2026-02-12 | -$0.33 10-Q · filed 2025-02-14 | -$0.45 10-Q · filed 2026-02-12 | -$0.76 10-Q · filed 2025-02-14 | -$0.64 derived: net income ÷ weighted average shares · filed 2026-03-20 | -$0.86 derived: net income ÷ weighted average shares · filed 2026-03-20 | ||
| 2024-09-30 | -$0.18 10-K/A · filed 2026-03-20 | -$0.48 10-Q · filed 2024-11-14 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-03-20 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-03-20 | -$1.12 derived: net income ÷ weighted average shares · filed 2026-03-20 | |||
| 2024-06-30 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-03-20 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-03-20 | -$1.02 derived: net income ÷ weighted average shares · filed 2026-03-20 | -$1.22 10-K/A · filed 2026-03-20 | -$5.51 10-K · filed 2024-09-26 | |||
| 2024-03-31 | -$0.23 10-Q · filed 2025-05-14 | -$1.64 10-Q · filed 2024-05-13 | -$1.06 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$1.11 10-Q · filed 2025-05-14 | -$6.95 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | -$2.64 10-Q · filed 2025-02-14 | -$5.65 10-Q · filed 2025-02-14 | -$5.39 10-Q · filed 2024-02-13 | |||||
| 2023-09-30 | -$3.05 10-Q · filed 2024-11-14 | -$2.76 10-Q · filed 2023-11-13 | ||||||
| 2023-06-30 | -$14.12 10-K · filed 2024-09-26 | |||||||
| 2023-03-31 | -$2.67 10-Q · filed 2024-05-13 | -$0.16 10-Q · filed 2023-05-15 | -$11.47 10-Q · filed 2024-05-13 | -$0.67 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | -$3.34 10-Q · filed 2024-02-13 | -$0.20 10-Q · filed 2023-02-13 | -$9.30 10-Q · filed 2024-02-13 | -$0.55 10-Q · filed 2023-02-13 | ||||
| 2022-09-30 | -$7.98 10-Q · filed 2023-11-13 | -$0.47 10-Q · filed 2022-11-10 | ||||||
| 2022-06-30 | -$37.88 10-K · filed 2023-09-21 | -$2.23 10-K · filed 2022-09-02 | ||||||
| 2022-03-31 | -$0.40 10-Q · filed 2023-05-15 | -$1.61 10-Q · filed 2023-05-15 | ||||||
| 2021-12-31 | -$0.59 10-Q · filed 2023-02-13 | -$1.21 10-Q · filed 2023-02-13 | ||||||
| 2021-09-30 | -$0.62 10-Q · filed 2022-11-10 | |||||||
| 2021-06-30 | -$3.23 10-K · filed 2022-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |